Nutrients · Nov 15, 2026

Clinical Evidence on the Effects of GLP-1 Receptor Agonists and Dual GIP/GLP-1 Receptor Agonists on Appetite, Food Preferences, and Eating Behavior: A Narrative Review

By Moszak M, Pelczyńska M, Cebula J et al.

Background: Incretin-based therapies have transformed obesity management, offering new opportunities to improve weight-related and cardiometabolic outcomes. However, their influence on eating behaviors and their core dimensions has not yet been comprehensively analyzed. Therefore, this narrative review aims to discuss the available clinical evidence regarding GLP-1 receptor agonists (GLP-1 RAs) and dual GLP-1/GIP receptor agonists (GIP/GLP-1 RAs) on eating behaviors in adults with obesity, including appetite, food preferences, food cravings, dietary intake, and diet quality. Methods: A narrative review of the literature was conducted to identify and analyze clinical studies assessing changes in eating behavior and diet-related outcomes during incretin-based pharmacological treatment for obesity. Studies evaluating GLP-1 RAs (e.g., liraglutide, semaglutide) and dual incretin agonists (tirzepatide) were included. Evidence from randomized clinical trials and observational studies examining appetite, energy intake, food preferences, and dietary behavior-related outcomes published before January 2026 was analyzed. Results: A total of 17 clinical studies met the eligibility criteria and were included in the narrative review. Available evidence suggests that incretin-based therapies reduced appetite and ad libitum energy intake, decreased cravings for energy-dense foods, and led to changes in food preferences. Some studies also report modifications in taste perception and greater control over eating behavior. Evidence regarding effects on dietary quality and macro- and micronutrient composition remains limited. Conclusions: GLP-1 RAs and GIP/GLP-1 RAs may affect multiple domains of eating behavior. Understanding these changes is important for optimizing dietary management during pharmacotherapy and for ensuring nutritionally balanced weight-loss strategies. Further research is needed to clarify the long-term effects of GLP-1 RAs and GIP/GLP-1 RAs on dietary habits and nutritional quality.

doi.org/10.3390/nu18223800Interventions

AgingResearch.News